Onconetix, Inc. revenue
Onconetix, Inc.'s revenue was $815,371 in fiscal 2025, down 67.7% on the year before. Over the last twelve months it was $645,824.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Other Revenues | $587,882 | 72.1% | — |
| Product Sales | $225,835 | 27.7% | ▼ 9.3% |
| Development Service | $1,654 | 0.2% | ▼ 99.9% |
| Licenses | $1 | 0.0% | — |
| Region | Revenue | YoY |
|---|---|---|
| European Union | $796,590 | ▼ 67.3% |
| Switzerland | $796,590 | ▼ 67.3% |
| Non European Union | $18,781 | ▼ 21.2% |
| United Kingdom | $18,781 | ▼ 21.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Onconetix, Inc.'s 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Onconetix, Inc. | $645,824 | -51.3% | — |
| Cardiff Oncology, Inc. | $508,000 | -7.0% | 7.2% |
| Medicinova Inc | $920,481 | 875.7% | — |
| Shattuck Labs, Inc. | $1.0m | -66.6% | 5.2% |
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
| Cervomed Inc. | $331,295 | -95.7% | -52.7% |
Compare with peers
- Cardiff Oncology, Inc. revenue
- Medicinova Inc revenue
- Shattuck Labs, Inc. revenue
- Longeveron Inc. revenue
- Cervomed Inc. revenue
Head to head: CRDF vs ONCOMNOV vs ONCOONCO vs STTK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies